Panitch Schwarze Belisario & Nadel LLP
Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
Crystalline free bases and crystalline acid salts of 9-((8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridine-3-yl)thio)-4-methyl-2H-[1,4]oxaazido[3,2-c]quinoline-3(4H)-one are disclosed as C-Met inhibitors. Their preparation methods and uses are also described. In particular, crystal forms I, II, III and IV of the free base; crystal form I of the hydrochloride salt; crystal forms I and II of the sulfate salt; crystal forms I, II, III and IV of the phosphate salt; crystal forms I, II, III, IV and V of the mesylate salt; crystal forms I, II and III of the p-toluenesulfonate salt; and crystal forms I, II and III of the 1,5-naphthalenedisulfonate salt are disclosed. Also disclosed are methods for preparing the above-mentioned crystal forms, pharmaceutical compositions thereof, methods for regulating the catalytic activity of a protein kinase, and methods of treating protein kinase-related diseases.
JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
A A A A A A A A C A C A A A A A
A61P A61P A61P A61K A61P A61P A61P A61P C07D A61P C07B A61P A61P A61P A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional
Aifeng Xiang
Lv Li